ANN ARBOR, MI--(Marketwire - November 26, 2007) - Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the Veterans Affairs (VA) Medical Center in Ann Arbor, MI to evaluate COPREXA (oral tetrathiomolybdate), its lead anti-copper drug candidate, in preclinical studies as a treatment for Huntington's Disease (HD), a life threatening and debilitating neurodegenerative disease.
